Quincy Attobrah

A USC study finds immunotherapy increases PAD risk by 60%. Experts advise vascular monitoring to help prevent limb loss in cancer survivors.

After a devastating pancreatic cancer diagnosis, Sharon chose a personalized treatment path that helped inspire future research.

The FDA approved Bizengri for NRG1+ cholangiocarcinoma, offering a new option for patients with this rare, advanced bile duct cancer.

Multiple myeloma death rates are declining as targeted therapies and immunotherapy improve survival, offering patients longer lives and more treatment options.

Elrexfio improved progression-free survival in multiple myeloma, helping patients live longer without disease worsening in a phase 3 trial.

Colorectal cancer is rising in younger adults. Dr. Jeremy Kortmansky, discusses causes, symptoms, screening barriers, and prevention.

FDA reviews Ziihera combinations for HER2-positive gastroesophageal cancer, showing potential benefit as a first-line treatment option for patients.

The National Ovarian Cancer Coalition (NOCC) delivers free meals to ovarian cancer patients, easing treatment burdens and supporting caregivers nationwide.

Study finds how multiple myeloma cells adapt to immunotherapy, helping explain why patients relapse and guiding personalized treatment approaches.

Treatment with Verzenio and letrozole may help control advanced or recurrent endometrial cancer for some patients, according to new research.

Diabetes drug metformin may mimic exercise effects in prostate cancer, supporting weight, metabolism and overall health during treatment.

CTIM-76 has received FDA fast track designation for platinum-resistant ovarian cancer, a step aimed at accelerating development for patients with few options.

Cogent submitted an FDA application for bezuclastinib after the phase 3 PEAK trial shows improved progression-free survival in patients with previously treated GIST.

The phase 3 EMERALD-3 trial shows Imfinzi and Imjudo plus Lenvima and embolization improved progression-free survival in unresectable liver cancer.

A study found blood-based genomic testing can be completed in 27 hours, giving patients with cancer faster treatment decisions.

New NCCN guidelines highlight personalized combo treatments and new options to help patients with advanced kidney cancer live longer, better lives.

In the phase 3 ATHENA-MONO trial, 5-year data show Rubraca helped delay cancer worsening in advanced ovarian cancer vs placebo.

Study shows home-based IV chemotherapy at Mayo Clinic was safely delivered with close monitoring, reducing treatment burden for patients with cancer.

Patients with cancer are referred for psychosocial support to address emotional distress and mental health needs, according to a new study.

Dr. Marleen Meyers discusses improving survival rates, the evolving needs of younger cancer survivors and how caregivers can sustain long-term support.

A structured exercise program may reduce cognitive decline, often referred to as “chemo brain,” in patients receiving chemotherapy for the first time.